Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Clinical trial NCT04380636 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04380636
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-06
- Primary completion
- 2027-05-05
- Enrollment
- 870
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.